Blueprint Medicines Initiating Phase I Trials for Two Investigational Cancer Drugs

Drug Industry Daily
A A
The FDA has given Blueprint Medicines the go-ahead to begin Phase I clinical trials for its investigational BLU-285 and BLU-554 to treat gastrointestinal tract, liver and biliary duct cancers.

To View This Article:

Login

Subscribe To Drug Industry Daily